Fig. 2.

Time on treatment and summary of responses. Intra-patient dose escalation was permitted to the highest cleared dose level, provided that the patient completed at least 2 cycles of RO7297089 at the originally assigned dose. Seven patients underwent intra-patient dose escalation and are detailed in the bar graph. MR minimal response, N/A assessment not done, PD progressive disease, PR partial response, SD stable disease, tx treatment. For patients with prior anti-BCMA treatment, all treatments consisted of belantamab mafodotin